IP Library Granted Patent US 9,394,258
Granted Patent B2
US 9,394,258 · App. 14/213,144 · Granted Jul 19, 2016

Arginine methyltransferase inhibitors and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,394,258
App. No.
14/213,144
Granted
Jul 19, 2016
Kind
B2
Abstract

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

Claims (40)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is NR 2 and Y is N; or

X is N and Y is NR 2 ;

each instance of R 1 is independently selected from the group consisting of halogen, —N 3 , —CN, —NO 2 , —OH, optionally substituted C 1-6 alkyl, and —OR A , wherein at least one instance of R 1 is —OR A ;

m is 1 or 2;

R 2 is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 3-6 cycloalkyl, or optionally substituted to 4- to 6-membered heterocyclyl;

R 3 is hydrogen, C 1-4 alkyl, or C 3-4 carbocyclyl;

R x is optionally substituted C 1-4 alkyl or optionally substituted C 3-4 carbocyclyl;

each instance of R A is independently selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 3-6 carbocyclyl, optionally substituted phenyl, optionally substituted 5- to 6-membered heterocyclyl, optionally substituted 5- to 6-membered heteroaryl, and optionally substituted C 1-6 alkyl-Cy;

each instance of Cy is independently optionally substituted C 3-6 cycloalkyl, optionally substituted 5- to 6-membered heterocyclyl, optionally substituted phenyl, or optionally substituted 5- to 6-membered heteroaryl; and

each instance of substituted independently refers to substitution with 1, 2, or 3 groups independently selected from the group consisting of —N 3 , halogen, —NO 2 , —CN, C 1-4 alkyl, and —OR aa , wherein each instance of R aa is independently C 1-4 alkyl.

2. The compound of claim 1 , wherein the compound is of Formula (II-a):

or a pharmaceutically acceptable salt thereof,

wherein:

R 4 is optionally substituted C 1-6 alkyl, optionally substituted C 3-6 carbocyclyl, optionally substituted phenyl, optionally substituted 5- to 6-membered heterocyclyl, optionally substituted 5- to 6-membered heteroaryl, or optionally substituted C 1-6 alkyl-Cy.

3. The compound of claim 2 , wherein R 4 is optionally substituted C 1-3 alkyl, optionally substituted C 5 carbocyclyl, optionally substituted phenyl, optionally substituted 5- to 6-membered heteroaryl or optionally substituted C 1-3 alkyl-Cy, wherein Cy is optionally substituted phenyl or optionally substituted 5- to 6-membered heteroaryl.

4. The compound of claim 2 , wherein the compound is of Formula (II-a1):

or a pharmaceutically acceptable salt thereof,

wherein:

n is 1, 2, 3, 4, 5, or 6;

R 4 is selected from the group consisting of:

each instance of R 6 is independently halogen, —N 3 , —CN, —NO 2 , or C 1-4 alkyl; and

p is 0, 1, 2, or 3.

5. The compound of claim 2 , wherein the compound is of Formula (II-a2):

or a pharmaceutically acceptable salt thereof,

wherein:

each instance of R 6 is independently halogen, —N 3 , —CN, —NO 2 , or C 1-4 alkyl; R B is hydrogen or C 1-4 alkyl;

n is 1, 2, 3, 4, 5, 6; and

q is 0, 1, or 2.

6. The compound of claim 1 , wherein X is NR 2 and Y is N.

7. The compound of claim 1 , wherein X is N and Y is NR 2 .

8. The compound of claim 1 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

9. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

10. A kit or packaged pharmaceutical comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and instructions for use thereof.

11. The compound of claim 1 , wherein R x is methyl, ethyl, isopropyl, propyl, butyl, hydroxyethyl, methoxyethyl, cyclopropyl, or cyclobutyl.

12. The compound of claim 1 , wherein R 3 is hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, or cyclobutyl.

13. A pharmaceutical composition comprising a compound of claim 8 , or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848 Recorded Aug 13, 2022
From: BIOPHARMA CREDIT PLC
To: EPIZYME, INC.
Reel/Frame 061165/0501 →
SECURITY INTEREST Recorded Nov 19, 2019
From: EPIZYME, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051057/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2014
From: CHESWORTH, RICHARD; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; KUNTZ, KEVIN WAYNE
To: EPIZYME, INC.
Reel/Frame 032943/0118 →